Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration‐sensitive prostate cancer: A multicenter retrospective study
Shingo Hatakeyama(Hirosaki University), Chikara Οhyama(Hirosaki University), Toshiaki Kawaguchi(Aomori Prefectural Central Hospital), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Teppei Okamoto(Hirosaki University), Norihiko Tsuchiya(Yamagata University), Jiro Shimoda(Iwate Prefectural Central Hospital), Masanori Ishida(Iwate Prefectural Central Hospital), Shigeto Ishidoya(Sendai City Hospital), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Senji Hoshi, Yoichi Arai(Japan Atomic Energy Agency), Toshihiko Sakurai(Sojo University), Masahiro Takahashi(Tohoku University), Hiromi Sato(Akita University), Shintaro Narita(Akita University), Itsuto Hamano(Hirosaki University)
Cited by 28
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253